Br Homeopath J 2000; 89(04): 161-168
DOI: 10.1054/homp.1999.0430
Original Paper
Copyright © The Faculty of Homeopathy 2000

Is homeopathic ‘immunotherapy’ effective? A double-blind, placebo-controlled trial with the isopathic remedy Betula 30c for patients with birch pollen allergy

S Aabel
1   Institute of General Practice and Community Medicine, Department of General Practice, PO Box 1130, Blindern, N-0317 Oslo, Norway
,
E Laerum
1   Institute of General Practice and Community Medicine, Department of General Practice, PO Box 1130, Blindern, N-0317 Oslo, Norway
,
S Dølvik
2   Department of Otorhinolaryngology, Ullevaal University Hospital, N-0407 Oslo, Norway
,
P Djupesland
2   Department of Otorhinolaryngology, Ullevaal University Hospital, N-0407 Oslo, Norway
› Author Affiliations

Subject Editor:
Further Information

Publication History

Received22 November 1999
revised04 July 2000

accepted10 July 2000

Publication Date:
28 May 2018 (online)

Abstract

The objective of the study was to examine the effect of the homeopathic remedy Betula 30c vs placebo for patients with birch pollen allergy. A double-blind, randomized, placebo-controlled trial was carried out. Tablets were given for 4 weeks during the birch pollen season. The setting was Oslo, Norway, May 1995.

Patients were aged between 18 and 50 y; 32 patients received Betula 30c tablets and 34 patients received placebo tablets.

The main outcome measure was the total score of 17 different allergy symptoms. Daily total scores were calculated, as well as differences and ratios between the run-in and the following time periods. Point estimates of the median difference between the experimental and placebo groups, with their 95% confidence intervals, were the main measure of effect.

No statistically significant difference between the groups was found during the first and last period of May. However, from 8 to 18 May, a clinically interesting difference was revealed between the groups, those receiving Betula 30c having fewer and less serious symptoms. For some days these differences were statistically significant. Surprisingly, this group reported more aggravation from the tablets than did the placebo group.

With a statistical power of 70% for a defined clinically interesting difference (25%), the present results indicate that treatment with Betula 30c during the pollen season deserves further attention.